Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | BMI1 | P35226 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674901 | 0.86 | TRPV1 (0.52) | TRPV1EPHX2 | |
| SCHEMBL15290320 | 0.84 | TRPV1 (0.46) | TRPV1EPHX2 | |
| SCHEMBL15290279 | 0.84 | TRPV1 (0.46) | TRPV1EPHX2 | |
| SCHEMBL15290346 | 0.84 | TRPV1 (0.46) | TRPV1EPHX2 | |
| SCHEMBL4678750 | 0.83 | TRPV1 (0.50) | TRPV1EPHX2 | |
| SCHEMBL4675585 | 0.81 | EPHX2 (0.64) | TRPV1EPHX2 | |
| SCHEMBL4674915 | 0.81 | EPHX2 (0.47) | TRPV1EGFRKDREPHX2PDGFRB | |
| SCHEMBL4676118 | 0.81 | EPHX2 (0.48) | TRPV1EGFRKDREPHX2PDGFRB | |
| SCHEMBL4675893 | 0.80 | KIF11 (0.44) | TRPV1EGFRKDREPHX2ABCG2 | |
| SCHEMBL4675297 | 0.80 | TRPV1 (0.65) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625119-B1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2008-07-23 | — | — | EP | claimed |
| US-20060229307-A1 | Substituted-1-phthalazinamines as vr-1 antagonists | MERCK SHARP & DOHME LTD. (GB) | 2006-10-12 | — | — | US | claimed |
| EP-1625119-B1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7329659-B2 | Substituted-1-phthalazinamines as vr-1 antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20060229307-A1 | Substituted-1-phthalazinamines as vr-1 antagonists | MERCK SHARP & DOHME LTD. (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1625119-A1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099177-A1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229307-A1 | Substituted-1-phthalazinamines as vr-1 antagonists | TRPV1, ARRB1, AVPR1A | TRPV1 1/4885EGFR 2360/4885KDR 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.